UCB, a global biopharmaceutical company, is presenting its research on generalized myasthenia gravis (gMG) at two annual meetings. It will present additional results from the MycarinG and RAISE studies on its drugs rozanolixizumab-noli and zilucoplan. Both drugs, recently approved by the US FDA and Japanese authorities, are under review by the European Medicines Agency for the treatment of adults with gMG. UCB is also assessing the drugs in pediatric patients with gMG.
LockBit ransomware group falls victim to hackers itself
A data leak has disclosed information about negotiations with victims, Bitcoin wallet addresses, affiliate accounts, and details of attacks.
